{"entity":{"id":"paper-raymond-sunitinib-pnet-nejm-2011","kind":"paper","name":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumours","aka":[],"tldr":"The multikinase inhibitor sunitinib doubled the time to progression in advanced pancreatic neuroendocrine tumours and was approved at the same time as everolimus, giving the disease its first targeted therapies.","summary":"Phase 3 placebo-controlled trial of 171 patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumours randomised to sunitinib 37.5 mg daily or placebo, stopped early after an independent monitoring committee observed more deaths and serious events with placebo.\n\nMedian progression-free survival was 11.4 versus 5.5 months (hazard ratio 0.42) with response of 9.3 versus 0 percent; hypertension, hand-foot syndrome and fatigue were the main toxicities.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2011","url":"https://doi.org/10.1056/NEJMoa1003825"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/21306237/"}],"tags":[],"related":[],"cancers":["pancreatic-net"],"sections":[],"technologies":[],"targets":[],"drugs":["sunitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2011,"doi":"10.1056/NEJMoa1003825","pmid":"21306237","authors":"Raymond E, Dahan L, Raoul JL, et al.","paperType":"rct","findings":["Median progression-free survival 11.4 vs 5.5 months; hazard ratio 0.42.","Objective response 9.3 percent vs 0 percent."],"whatItMeans":"Sunitinib is a standard targeted option for progressive pancreatic neuroendocrine tumours; the choice between it and everolimus is guided by comorbidity and side-effect profile.","caveats":["Trial stopped early with 171 of a planned 340 patients, which can overestimate effect."],"changedPractice":true,"participants":171},"route":"/key-papers/paper-raymond-sunitinib-pnet-nejm-2011/","neighbours":{"cancer":[{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/"}],"drug":[{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}